Jiafu Liu, Ran Wei, Xiaoxing Miao, Jinbo Han, Jie Wang
UIMT should be considered in the differential diagnosis of urachal or anterosuperior bladder-wall masses. Definitive diagnosis requires integrated histopathological and immunohistochemical assessment, and complete resection with negative margins is the preferred treatment for localized, resectable disease.
BACKGROUND: Inflammatory myofibroblastic tumor (IMT) is an uncommon mesenchymal neoplasm. Urachal involvement is exceedingly rare, and evidence regarding its clinical presentation, diagnosis, and management remains limited.
CASE PRESENTATION: We report the case of a 62-year-old female patient who presented with urinary frequency and dysuria for 8 days. Computed tomography (CT) revealed a mass at the junction of the urachus and the anterosuperior wall of the bladder, which was further confirmed by cystoscopy. The patient underwent laparoscopic resection of the urachal mass combined with partial cystectomy. Histopathological examination of the surgical specimen confirmed IMT, and immunohistochemical staining was positive for anaplastic lymphoma kinase (ALK) and vimentin. At the 3-month postoperative follow-up, CT and cystoscopy showed no evidence of local recurrence.
CONCLUSION: UIMT should be considered in the differential diagnosis of urachal or anterosuperior bladder-wall masses. Definitive diagnosis requires integrated histopathological and immunohistochemical assessment, and complete resection with negative margins is the preferred treatment for localized, resectable disease.